GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the nine-month period ended September 30, 2014 and for the year ended December 31, 2013 are as follows:



	Clinical Diagnostics Laboratory Segment					Other Segment						Total
	September 30, 2014		December 31, 2013			September 30, 2014			December 31, 2013			September 30, 2014			December 31, 2013
Balance as of January 1	$	2,960.2	$	2,857.1		$	62.6		$	44.6		$	3,022.8		$	2,901.7
Goodwill acquired during the period	46.7		107.5			—			19.5			46.7			127.0
Adjustments to goodwill	—		(4.4		)	(3.1		)	(1.5		)	(3.1		)	(5.9		)
Balance at end of period	$	3,006.9	$	2,960.2		$	59.5		$	62.6		$	3,066.4		$	3,022.8

The components of identifiable intangible assets are as follows:



	September 30, 2014							December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Customer relationships	$	1,337.9	$	(591.4	)	$	746.5	$	1,327.0	$	(545.1	)	$	781.9
Patents, licenses and technology	120.7		(93.3		)	27.4		116.2		(85.4		)	30.8
Non-compete agreements	44.6		(30.1		)	14.5		41.6		(25.3		)	16.3
Trade names	131.3		(89.4		)	41.9		131.4		(83.0		)	48.4
Canadian licenses	659.1		—			659.1		694.6		—			694.6
	$	2,293.6	$	(804.2	)	$	1,489.4	$	2,310.8	$	(738.8	)	$	1,572.0

Amortization of intangible assets for the three and nine month periods ended September 30, 2014 was $18.3 and $61.3, respectively; and $20.3 and $60.3 for the three and nine month periods ended September 30, 2013, respectively. Amortization expense for the net carrying amount of intangible assets is estimated to be $20.1 for the remainder of fiscal 2014, $82.6 in fiscal 2015, $77.3 in fiscal 2016, $70.1 in fiscal 2017, $59.3 in fiscal 2018 and $500.7 thereafter.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details